VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, December 31, 2025
Stock Comparison
Gilead Sciences, Inc. vs Stryker Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisStryker Corporation
SYK · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Stryker Corporation's moat claims, evidence, and risks.
View SYK analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 71 / 100 for Stryker Corporation).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Stryker Corporation has 2 segments (59.8% in MedSurg and Neurotechnology).
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Stryker Corporation has 5 across 3.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Stryker Corporation
MedSurg and Neurotechnology
Hospital medical devices: surgical equipment and navigation, endoscopy and visualization, patient handling and emergency care, neurosurgical and neurovascular devices
Global
Hospitals and ambulatory surgery centers; clinicians
Medical device OEM + distributor/service provider
59.8%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Stryker Corporation strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Stryker Corporation segments
Full profile >MedSurg and Neurotechnology
Oligopoly
Orthopaedics
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.